Together with the tumor size (Fig 7F) and the survival data (Fig 7G), these experiments confirmed that XBP1+/RIDD− tumor cells yielded the most aggressive tumors whereas injecting XBP1−/RIDD+ tumor cells resulted in very small tumors, thereby confirming the results observed in patients’ tumors (Fig 6). Here, XBP1 is linked to neoplasm.